Talis Biomedical to Announce First Quarter 2022 Financial Results on May 10, 2022

Rhea-AI Summary

Talis Biomedical Corporation (TLIS) has announced that it will report its first quarter financial results on May 10, 2022, after market close. The company will host a conference call at 1:30 PM PT (4:30 PM ET) to discuss these results. Interested parties can join via telephone or watch the webcast on their investor website. Talis is focused on improving health equity through accurate infectious disease testing, particularly with its Talis One system, which has received Emergency Use Authorization from the FDA for COVID-19 testing.

Positive

• Upcoming financial report scheduled for May 10, 2022.
• Talis One system received Emergency Use Authorization from the FDA.

Negative

• None.

MENLO PARK, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation ("TLIS"), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will report first quarter financial results on Tuesday, May 10, 2022, after market close. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).

Interested parties may access the live call via telephone by dialing 833-715-1329 for participants in the U.S. or Canada and 430-775-1933 for international callers, using conference ID 8872347. A live and archived webcast of the event can be accessed via the News & Events page of the investor section of Talis Biomedical’s website at www.talis.bio.

About Talis Biomedical
Talis is dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care. The company plans to develop and commercialize innovative products on its sample-to-answer Talis One^TM system to enable accurate, low cost, and rapid molecular testing. The U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for use of the Talis One COVID-19 Test System in a variety of healthcare settings. For more information, visit talisbio.com.

Contact
Media & Investors
Emily Faucette
ir@talisbio.com
415-595-9407

FAQ

When will Talis Biomedical report its first quarter financial results for 2022?

Talis Biomedical will report its first quarter financial results on May 10, 2022, after market close.

What is the conference call time for Talis Biomedical's financial results?

The conference call will begin at 1:30 PM Pacific Time (4:30 PM Eastern Time) on May 10, 2022.

How can I access Talis Biomedical's financial results conference call?

You can access the call by dialing 833-715-1329 for U.S. participants or 430-775-1933 for international callers, using conference ID 8872347.

What product does Talis Biomedical focus on for infectious disease testing?

Talis Biomedical focuses on the Talis One system for accurate infectious disease testing.

Has Talis Biomedical received any regulatory approvals for its products?

Yes, Talis Biomedical has received Emergency Use Authorization from the FDA for the Talis One COVID-19 Test System.